IN2014DN09582A - - Google Patents

Info

Publication number
IN2014DN09582A
IN2014DN09582A IN9582DEN2014A IN2014DN09582A IN 2014DN09582 A IN2014DN09582 A IN 2014DN09582A IN 9582DEN2014 A IN9582DEN2014 A IN 9582DEN2014A IN 2014DN09582 A IN2014DN09582 A IN 2014DN09582A
Authority
IN
India
Prior art keywords
assays
microcuiture
disclosed
methods
kinetic assays
Prior art date
Application number
Other languages
English (en)
Inventor
Cary Presant
Mathieu Perree
Allan Hallquist
Original Assignee
Diatech Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatech Oncology Llc filed Critical Diatech Oncology Llc
Publication of IN2014DN09582A publication Critical patent/IN2014DN09582A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G01N33/575
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9582DEN2014 2012-05-15 2013-03-14 IN2014DN09582A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647248P 2012-05-15 2012-05-15
PCT/US2013/031300 WO2013172955A1 (en) 2012-05-15 2013-03-14 Tumor cell isolation/purification process and methods for use thereof

Publications (1)

Publication Number Publication Date
IN2014DN09582A true IN2014DN09582A (enExample) 2015-07-17

Family

ID=49584132

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9582DEN2014 IN2014DN09582A (enExample) 2012-05-15 2013-03-14

Country Status (17)

Country Link
US (2) US20150160193A1 (enExample)
EP (1) EP2850434A4 (enExample)
JP (1) JP2015517662A (enExample)
KR (1) KR20150035537A (enExample)
CN (1) CN104704368A (enExample)
AU (1) AU2013263337A1 (enExample)
BR (1) BR112014028396A2 (enExample)
CA (1) CA2873180A1 (enExample)
CO (1) CO7240391A2 (enExample)
CR (1) CR20140575A (enExample)
HK (1) HK1208727A1 (enExample)
IL (1) IL235709A0 (enExample)
IN (1) IN2014DN09582A (enExample)
MX (1) MX2014013939A (enExample)
SG (1) SG11201407497TA (enExample)
TW (1) TW201409029A (enExample)
WO (1) WO2013172955A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324657B2 (en) 2007-11-28 2025-06-10 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
ES2731824T3 (es) * 2013-02-06 2019-11-19 Intervet Inc Sistema para determinar la eficacia de los antibióticos en enfermedades respiratorias mediante el análisis de auscultación
LT3083686T (lt) 2013-12-17 2020-01-10 F. Hoffmann-La Roche Ag Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
MD3423105T2 (ro) 2016-03-02 2021-10-31 Eisai R&D Man Co Ltd Conjugați anticorp-medicament pe bază de eribulină și metode de utilizare
BR112020018892A2 (pt) * 2018-03-20 2021-02-09 Lumacyte, LLC monitoramento e quantificação celular biofísica e bioquímica avançada ao usar citologia de força laser
TWI662130B (zh) * 2018-09-21 2019-06-11 國立臺灣大學 分離循環癌細胞之方法
CN111019897B (zh) * 2019-02-14 2023-08-11 中山大学孙逸仙纪念医院 人良性叶状肿瘤细胞系glk-1010及其应用
CN111019899B (zh) * 2019-02-14 2023-08-04 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系lj-0429及其应用
CN111019898B (zh) * 2019-02-14 2023-07-21 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系hjp-0320及其应用
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
WO2024054627A1 (en) * 2022-09-08 2024-03-14 The University Of North Carolina At Chapel Hill Diagnosis of patient tumor tissue
CN115747290A (zh) * 2022-11-23 2023-03-07 零壹人工智能科技研究院(南京)有限公司 一种对肠癌类器官进行药敏测试的新操作方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251186A1 (en) * 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
AU2002239491A1 (en) * 2000-11-09 2002-05-27 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
KR100721927B1 (ko) * 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
IT1391619B1 (it) * 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
BR112012024619A2 (pt) * 2010-03-31 2016-05-31 Diatech Oncology Llc sistema e método para avaliação de candidato a medicamento anticancer
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Also Published As

Publication number Publication date
TW201409029A (zh) 2014-03-01
SG11201407497TA (en) 2014-12-30
JP2015517662A (ja) 2015-06-22
AU2013263337A1 (en) 2014-12-04
WO2013172955A9 (en) 2014-02-27
CR20140575A (es) 2015-05-07
CA2873180A1 (en) 2013-11-21
CO7240391A2 (es) 2015-04-17
KR20150035537A (ko) 2015-04-06
BR112014028396A2 (pt) 2018-05-29
MX2014013939A (es) 2015-05-11
CN104704368A (zh) 2015-06-10
EP2850434A1 (en) 2015-03-25
IL235709A0 (en) 2015-01-29
EP2850434A4 (en) 2016-01-13
US20170336391A1 (en) 2017-11-23
US20150160193A1 (en) 2015-06-11
HK1208727A1 (en) 2016-03-11
WO2013172955A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
IN2014DN09582A (enExample)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
EP2858722B8 (en) Compostions and methods for cancer immunotherapy
HK1205454A1 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MY186099A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014018563A3 (en) Methods for the treatment of cancer
WO2012135675A3 (en) Methods for increasing efficacy of folr1 cancer therapy
PH12014501844B1 (en) Peptidomimetic macrocycles
WO2013056148A3 (en) Scd1 antagonists for treating cancer
AU2012209332A8 (en) Methods and compositions for preparing noribogaine from voacangine
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
PH12021550360A1 (en) Treatment of brain cancer
EP2867376A4 (en) TARGETED METHODS KNOWN AS RNA-SEQ AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCER
WO2013149171A3 (en) Methods for increasing efficacy of cd37-based therapy
EP2694972B8 (en) Methods for predicting and improving the survival of gastric cancer patients
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
WO2013025939A9 (en) Compounds and methods for treating cancer by inhibiting the urokinase receptor
IN2014DN07103A (enExample)
EP2601337B8 (en) Method for the production of pockets for wallets and relative equipment.
MX2012007797A (es) Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
WO2014013511A3 (en) Rufinamide solid dispersion